Upgrade to SI Premium - Free Trial

Raymond James on Biohaven Pharma (BHVN): 'results continue to highlight an opportunity for opakalim'

March 9, 2026 1:55 PM
Raymond James analyst Chris Raymond reiterated a Strong Buy rating and $50.00 price target on Biohaven Pharma (NYSE: BHVN).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot Comments